Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: A Spanish Lung Cancer Group trial

Annals of Oncology

Volumn 17, Issue 3, 2006, Pages 467-472

  Camps, C ^a   Massuti, B ^b   Jimenez A ^c   Maestu, I ^d   Garcia Gomez R ^e   Isla, D ^f   Gonzalez J L ^g   Almenar, D ^h   Blasco, A ^a   Rosell, R ⁱ   Carrato, A ^j   Vinolas N ^k   Batista, N ^l   Garcia Giron C ^m   Galan A ⁿ   Lopez M ^o   Blanco, R ^p   Provencio, M ^q   Diz, P ^r   Felip, E ^s  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^d HOSPITAL VIRGEN DE LOS LIRIOS   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h HOSPITAL UNIVERSITARIO DR PESET   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^k HOSPITAL CLÍNIC   (Spain)

^l HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^m HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

ⁿ HOSPITAL DE SAGUNTO   (Spain)

^o HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^p Brain   (Spain)

^q HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^r HOSPITAL DE LEÓN   (Spain)

^s HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

more..

Author keywords

Docetaxel; Non small cell lung cancer; Second line chemotherapy

Indexed keywords

DEXAMETHASONE; DOCETAXEL; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SPAIN; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 33644694366     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj115     Document Type: Article

References (18)

1. Parkin DM, Bray FI, Devessa SS. Cancer burden for the year 2000: The global picture. Eur J Cancer 2001; 37 (Suppl 8): S4-S66.
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311: 899-909.
3. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18: 2354-2362.
4. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
5. Hainsworth JD, Burris HA 3rd, Erland JB et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16: 2164-2168.
6. Lilenbaum RC, Schwartz MA, Seigel L et al. Phase II trial of weekly docetaxel in second-line therapy for non-small cell lung carcinoma. Cancer 2001; 92: 2158-2163.
7. Pocock S, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-111.
8. National Cancer Institute. Cancer Therapy Evaluation Program: Guidelines for the Reporting of Adverse Drug Reactions. Common Toxicity Criteria version 2.0 (CTC), 1999; http://ctep.cancer.gov/reporting/CTC-3.html (15 December 2005, date last accessed).
9. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
10. American Society of Clinical Oncology. Treatment of unresectable non-small-cell lung cancer guideline. J Clin Oncol 2004; 2: 330-353.
11. Hanna NH, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
12. 2) as second-line monotherapy for non-small-cell lung cancer. Ann Oncol 2004; 15: 38-44.
13. Gervais R, Ducolone A, Breton JL et al. Phase II randomized trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005; 16: 90-96.
14. Gridelli C, Gallo C, Di Maio M et al. A randomized clinical trial of two docetaxel regimens (weekly vs every 3 weekly) in the second-line treatment of nonsmall-cell lung cancer: The DISTAL 01 study. Br J Cancer 2004; 91: 1996-2004.
15. Schuette W, Nagel S, Serke M et al. Weekly versus three-weekly docetaxel as second-line chemotherapy for advanced non-small cell lung cancer (NSCLC): Updated results of a randomized phase III study. European Society Medical Oncology 2004 (Abstr 633).
16. Esteban E, González de Sande L, Fernández W et al. Prospective randomised phase II study of docetaxel versus paclitaxel administer weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol 2003; 14: 1640-1647.
17. Socinski M, Schell MJ, Bakri K et al. Second-line, low dose, weekly paclitaxel in patients with stage IIIB/IV non-small cell lung carcinoma who fails first-line chemotherapy with carboplatin plus paclitaxel. Cancer 2002; 95: 1265-1273.
18. Hoang T, Xu R, Schiller JH et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol 2005; 23: 175-183.